Irritable bowel syndrome accompanied by diarrhea (IBS-D) is a functional gastrointestinal disease that patients often take interventions based on symptom relief, but effective treatment options are still limited.
, a randomized controlled study published in Am J Gastroenterol confirmed that Irusadolin is effective and safe in treating gastrointestinal symptoms in patients with IBS-D.
study randomly assigned 346 adult IBS-D patients to a placebo or Irusadolin 100 mg twice a day for 12 weeks.
daily IBS-D symptoms in patients, including the most severe abdominal pain (WAP) and stool consistency.
the main endpoint is the proportion of respondents, defined as patients with at least 50 per cent of treatment days meeting the daily composite response criteria (WAP improvement≥40 per cent, Bristol stool scale score of 5≥60 days recorded over 12 weeks.
results showed that over a 12-week period, the Arushadolin group reached the primary composite reactor endpoint (22.7% vs. 10.3%, P s. 0.002), and the stool consistency improved (27.9% vs 16.7%, P s 0.01) and WAP improvement (43.6% vs 31.0%, P s 0.02) significantly increased the proportion of patients.
addition, more patients in the Irusadolin group reached the comprehensive respondent endpoint of the monthly interval assessment (weeks 1-4: 14.0% vs. 6.9%, P s 0.03; Week 8: 26.7% vs 14.9%, P s 0.006; Week 9-12: 30.8% vs 16.7%, P s 0.002).
the rates of adverse events were comparable in both groups (37.4% vs 35.3%);
the proportion of weekly compound responders during the 12-week treatment, the results show that Irusadolin appears to be safe and effective in treating IBS-D symptoms in patients with poor gallbladder treatment.